[6-(2,6-dimethyl-phenyl)-quinazolin-2-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine | 1234096-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: [6-(2,6-dimethyl-phenyl)-quinazolin-2-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine
• 英文别名: 6-(2,6-dimethylphenyl)-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]quinazolin-2-amine
• CAS: 1234096-22-0
• 化学式: C₂₈H₃₀N₄O
• 分子量: 438.572
• InChiKey: XMEMWQHGCLIHOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  50.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(2-(4-溴苯氧基)乙基)吡咯烷 、 6-(2,6-dimethyl-phenyl)-quinazolin-2-ylamine 在 5-二叔丁基膦-1′,3′,5′-三苯基-1′H-[1,4′]二吡唑 、 tris-(dibenzylideneacetone)dipalladium(0) potassium hydroxide 作用下， 以 tertamylacohol 、 水 为溶剂， 反应 5.0h， 以12%的产率得到[6-(2,6-dimethyl-phenyl)-quinazolin-2-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine
  参考文献：
  名称：

  [EN] SUBSTITUTED QUINAZOLINE COMPOUNDS
  [FR] COMPOSÉS QUINAZOLINE SUBSTITUÉS

  摘要：

  本发明涉及某些新颖化合物、生产它们的方法以及治疗或改善激酶介导的疾病的方法。更具体地说，本发明涉及取代喹唑啉化合物，其可用作选择性激酶抑制剂，生产这种化合物的方法以及治疗或改善激酶介导的疾病的方法。特别是，这些方法涉及治疗或改善激酶介导的疾病，包括心血管疾病、糖尿病、与糖尿病相关的疾病、炎症性疾病、免疫性疾病、癌症和眼部疾病，如视网膜病变、黄斑退化或其他玻璃体视网膜疾病等。

  公开号：

  WO2010076238A1

文献信息

• SUBSTITUTED QUINAZOLINE COMPOUNDS
  申请人：Leriche Caroline

  公开号：US20120004210A1

  公开（公告）日：2012-01-05

  The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.
• US8389530B2
  申请人：——

  公开号：US8389530B2

  公开（公告）日：2013-03-05
• [EN] SUBSTITUTED QUINAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS QUINAZOLINE SUBSTITUÉS
  申请人：FOVEA PHARMACEUTICALS SA

  公开号：WO2010076238A1

  公开（公告）日：2010-07-08

  The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.

  本发明涉及某些新颖化合物、生产它们的方法以及治疗或改善激酶介导的疾病的方法。更具体地说，本发明涉及取代喹唑啉化合物，其可用作选择性激酶抑制剂，生产这种化合物的方法以及治疗或改善激酶介导的疾病的方法。特别是，这些方法涉及治疗或改善激酶介导的疾病，包括心血管疾病、糖尿病、与糖尿病相关的疾病、炎症性疾病、免疫性疾病、癌症和眼部疾病，如视网膜病变、黄斑退化或其他玻璃体视网膜疾病等。